TY - JOUR
T1 - Vagus nerve stimulation with tachycardia detection provides additional seizure reduction compared to traditional vagus nerve stimulation
AU - Datta, Proleta
AU - Galla, Krishna Mourya
AU - Sajja, Kalyan
AU - Wichman, Christopher
AU - Wang, Hongmei
AU - Madhavan, Deepak
N1 - Funding Information:
This study was funded by a grant from LivaNova Inc., USA.
Funding Information:
This study was funded by a grant from LivaNova Inc., USA.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/10
Y1 - 2020/10
N2 - Purpose: This study investigates the clinical and cost effectiveness of switching from traditional vagus nerve stimulation (VNS) to responsive VNS (rVNS), which has an additional ictal tachycardia detection and stimulation (AutoStim) mode. Methods: Retrospective chart review was used to collect data from patients with medically refractory epilepsy who underwent generator replacements. Patients with confounding factors such as medication changes were excluded. Vagus nerve stimulation parameters, seizure frequency, and healthcare costs were collected for the 1-year period following generator replacement with the rVNS device. Results: Documented seizure frequency was available for twenty-five patients. After implant with rVNS, 28% of patients had an additional ≥ 50% seizure reduction. There was a significant decrease in the average monthly seizure count (p = 0.039). In patients who were not already free of disabling seizures (n = 17), 41.2% had ≥ 50% additional seizure reduction. There was no difference in healthcare costs during the 1-year follow-up after the rVNS implant compared with one year prior. Conclusions: Ictal tachycardia detection and stimulation provided a significant clinical benefit in patients who were not free of disabling seizures with treatment from traditional VNS. There was no additional increase in healthcare costs during the first year after device replacement.
AB - Purpose: This study investigates the clinical and cost effectiveness of switching from traditional vagus nerve stimulation (VNS) to responsive VNS (rVNS), which has an additional ictal tachycardia detection and stimulation (AutoStim) mode. Methods: Retrospective chart review was used to collect data from patients with medically refractory epilepsy who underwent generator replacements. Patients with confounding factors such as medication changes were excluded. Vagus nerve stimulation parameters, seizure frequency, and healthcare costs were collected for the 1-year period following generator replacement with the rVNS device. Results: Documented seizure frequency was available for twenty-five patients. After implant with rVNS, 28% of patients had an additional ≥ 50% seizure reduction. There was a significant decrease in the average monthly seizure count (p = 0.039). In patients who were not already free of disabling seizures (n = 17), 41.2% had ≥ 50% additional seizure reduction. There was no difference in healthcare costs during the 1-year follow-up after the rVNS implant compared with one year prior. Conclusions: Ictal tachycardia detection and stimulation provided a significant clinical benefit in patients who were not free of disabling seizures with treatment from traditional VNS. There was no additional increase in healthcare costs during the first year after device replacement.
KW - AspireSR®
KW - Medically refractory epilepsy
KW - Neurostimulation
KW - Responsive vagus nerve stimulation (rVNS)
KW - Vagus nerve stimulation (VNS)
UR - http://www.scopus.com/inward/record.url?scp=85088533820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088533820&partnerID=8YFLogxK
U2 - 10.1016/j.yebeh.2020.107280
DO - 10.1016/j.yebeh.2020.107280
M3 - Article
C2 - 32759064
AN - SCOPUS:85088533820
SN - 1525-5050
VL - 111
JO - Epilepsy and Behavior
JF - Epilepsy and Behavior
M1 - 107280
ER -